nodes	percent_of_prediction	percent_of_DWPC	metapath
Acamprosate—GRM5—GPCRs, Class C Metabotropic glutamate, pheromone—GRM4—bone cancer	0.0465	0.116	CbGpPWpGaD
Acamprosate—GRM5—GPCRs, Class C Metabotropic glutamate, pheromone—GRM1—bone cancer	0.0403	0.1	CbGpPWpGaD
Acamprosate—GRM5—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.022	0.0546	CbGpPWpGaD
Acamprosate—GRM5—Class C/3 (Metabotropic glutamate/pheromone receptors)—GRM4—bone cancer	0.0212	0.0527	CbGpPWpGaD
Acamprosate—GRM5—Class C/3 (Metabotropic glutamate/pheromone receptors)—GRM1—bone cancer	0.0184	0.0457	CbGpPWpGaD
Acamprosate—GRIN2C—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.0141	0.0349	CbGpPWpGaD
Acamprosate—GRIN2D—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.0131	0.0325	CbGpPWpGaD
Acamprosate—GRIN2A—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.0107	0.0267	CbGpPWpGaD
Acamprosate—GRIN1—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.00937	0.0233	CbGpPWpGaD
Acamprosate—GRIN2B—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.00913	0.0227	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—FEV—bone cancer	0.0078	0.0194	CbGpPWpGaD
Acamprosate—GRM5—G alpha (q) signalling events—GRM1—bone cancer	0.00536	0.0133	CbGpPWpGaD
Acamprosate—GRIN2C—CREB phosphorylation through the activation of Ras—BRAF—bone cancer	0.00488	0.0121	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.00479	0.0119	CbGpPWpGaD
Acamprosate—GRIN2D—CREB phosphorylation through the activation of Ras—BRAF—bone cancer	0.00454	0.0113	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—FEV—bone cancer	0.00441	0.011	CbGpPWpGaD
Acamprosate—GRIN1—Mecp2 and Associated Rett Syndrome—EZH2—bone cancer	0.00435	0.0108	CbGpPWpGaD
Acamprosate—GRIN2C—Post NMDA receptor activation events—BRAF—bone cancer	0.00402	0.00997	CbGpPWpGaD
Acamprosate—GRIN2D—Post NMDA receptor activation events—BRAF—bone cancer	0.00373	0.00927	CbGpPWpGaD
Acamprosate—GRIN2A—CREB phosphorylation through the activation of Ras—BRAF—bone cancer	0.00372	0.00925	CbGpPWpGaD
Acamprosate—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.0037	0.00919	CbGpPWpGaD
Acamprosate—GRM5—G alpha (q) signalling events—GNA11—bone cancer	0.00345	0.00858	CbGpPWpGaD
Acamprosate—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.00344	0.00854	CbGpPWpGaD
Acamprosate—GRIN1—CREB phosphorylation through the activation of Ras—BRAF—bone cancer	0.00325	0.00807	CbGpPWpGaD
Acamprosate—GRIN2B—CREB phosphorylation through the activation of Ras—BRAF—bone cancer	0.00317	0.00787	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—GRM4—bone cancer	0.00312	0.00774	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.00309	0.00767	CbGpPWpGaD
Acamprosate—GRIN2A—Post NMDA receptor activation events—BRAF—bone cancer	0.00307	0.00761	CbGpPWpGaD
Acamprosate—GABRB3—Orphan transporters—TUBB4B—bone cancer	0.00295	0.00733	CbGpPWpGaD
Acamprosate—GABRG2—Orphan transporters—TUBB4B—bone cancer	0.0029	0.0072	CbGpPWpGaD
Acamprosate—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.00282	0.00701	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—GRM1—bone cancer	0.0027	0.00671	CbGpPWpGaD
Acamprosate—GRIN1—Post NMDA receptor activation events—BRAF—bone cancer	0.00267	0.00664	CbGpPWpGaD
Acamprosate—GRIN2B—Post NMDA receptor activation events—BRAF—bone cancer	0.00261	0.00647	CbGpPWpGaD
Acamprosate—GABRB3—Orphan transporters—TUBB2A—bone cancer	0.00255	0.00633	CbGpPWpGaD
Acamprosate—GABRA1—Orphan transporters—TUBB4B—bone cancer	0.00254	0.0063	CbGpPWpGaD
Acamprosate—GABRG2—Orphan transporters—TUBB2A—bone cancer	0.0025	0.00622	CbGpPWpGaD
Acamprosate—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.00246	0.00612	CbGpPWpGaD
Acamprosate—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.0024	0.00596	CbGpPWpGaD
Acamprosate—GRIN2B—ErbB4 signaling events—MDM2—bone cancer	0.00228	0.00567	CbGpPWpGaD
Acamprosate—GABRA1—Orphan transporters—TUBB2A—bone cancer	0.00219	0.00543	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—EIF2S1—bone cancer	0.00208	0.00516	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—EIF2S1—bone cancer	0.00203	0.00503	CbGpPWpGaD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00194	0.00483	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—SMO—bone cancer	0.0019	0.00473	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—GRM4—bone cancer	0.00176	0.00437	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—RGS1—bone cancer	0.00176	0.00437	CbGpPWpGaD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00168	0.00417	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—GRM4—bone cancer	0.0016	0.00397	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—RGS1—bone cancer	0.0016	0.00397	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—GRM1—bone cancer	0.00153	0.00379	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—GRM1—bone cancer	0.00139	0.00344	CbGpPWpGaD
Acamprosate—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.00138	0.00344	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—EIF2S1—bone cancer	0.00137	0.0034	CbGpPWpGaD
Acamprosate—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.00129	0.0032	CbGpPWpGaD
Acamprosate—GRIN1—EPH-Ephrin signaling—MMP2—bone cancer	0.0012	0.00297	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—CDK4—bone cancer	0.00119	0.00297	CbGpPWpGaD
Acamprosate—GRIN2B—EPH-Ephrin signaling—MMP2—bone cancer	0.00117	0.00289	CbGpPWpGaD
Acamprosate—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.00116	0.00288	CbGpPWpGaD
Acamprosate—Pain—Cisplatin—bone cancer	0.00109	0.00182	CcSEcCtD
Acamprosate—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.00109	0.00182	CcSEcCtD
Acamprosate—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.00108	0.00268	CbGpPWpGaD
Acamprosate—Abdominal distension—Doxorubicin—bone cancer	0.00107	0.00179	CcSEcCtD
Acamprosate—Stomatitis—Methotrexate—bone cancer	0.00107	0.00179	CcSEcCtD
Acamprosate—Dysphagia—Doxorubicin—bone cancer	0.00106	0.00178	CcSEcCtD
Acamprosate—Asthma—Doxorubicin—bone cancer	0.00106	0.00178	CcSEcCtD
Acamprosate—Influenza—Doxorubicin—bone cancer	0.00106	0.00178	CcSEcCtD
Acamprosate—Pollakiuria—Epirubicin—bone cancer	0.00106	0.00178	CcSEcCtD
Acamprosate—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.00106	0.00263	CbGpPWpGaD
Acamprosate—Eosinophilia—Doxorubicin—bone cancer	0.00105	0.00176	CcSEcCtD
Acamprosate—GRIN2C—Alzheimers Disease—TP53—bone cancer	0.00105	0.00261	CbGpPWpGaD
Acamprosate—Sweating—Methotrexate—bone cancer	0.00105	0.00176	CcSEcCtD
Acamprosate—Photosensitivity reaction—Epirubicin—bone cancer	0.00105	0.00176	CcSEcCtD
Acamprosate—Feeling abnormal—Cisplatin—bone cancer	0.00105	0.00176	CcSEcCtD
Acamprosate—Weight increased—Epirubicin—bone cancer	0.00105	0.00175	CcSEcCtD
Acamprosate—Haematuria—Methotrexate—bone cancer	0.00104	0.00175	CcSEcCtD
Acamprosate—Pancreatitis—Doxorubicin—bone cancer	0.00104	0.00175	CcSEcCtD
Acamprosate—GRIN2C—Transmission across Chemical Synapses—BRAF—bone cancer	0.00104	0.00259	CbGpPWpGaD
Acamprosate—Weight decreased—Epirubicin—bone cancer	0.00104	0.00174	CcSEcCtD
Acamprosate—GRIN1—Spinal Cord Injury—RB1—bone cancer	0.00104	0.00258	CbGpPWpGaD
Acamprosate—Hyperglycaemia—Epirubicin—bone cancer	0.00104	0.00174	CcSEcCtD
Acamprosate—Angina pectoris—Doxorubicin—bone cancer	0.00104	0.00173	CcSEcCtD
Acamprosate—Epistaxis—Methotrexate—bone cancer	0.00103	0.00173	CcSEcCtD
Acamprosate—Pneumonia—Epirubicin—bone cancer	0.00103	0.00173	CcSEcCtD
Acamprosate—Bronchitis—Doxorubicin—bone cancer	0.00102	0.00171	CcSEcCtD
Acamprosate—Body temperature increased—Cisplatin—bone cancer	0.00101	0.00168	CcSEcCtD
Acamprosate—Stomatitis—Epirubicin—bone cancer	0.000999	0.00167	CcSEcCtD
Acamprosate—Urinary tract infection—Epirubicin—bone cancer	0.000996	0.00167	CcSEcCtD
Acamprosate—Haemoglobin—Methotrexate—bone cancer	0.000988	0.00165	CcSEcCtD
Acamprosate—GRM5—GPCR downstream signaling—GNA11—bone cancer	0.000984	0.00244	CbGpPWpGaD
Acamprosate—Hepatitis—Methotrexate—bone cancer	0.000983	0.00165	CcSEcCtD
Acamprosate—Haemorrhage—Methotrexate—bone cancer	0.000983	0.00165	CcSEcCtD
Acamprosate—Sweating—Epirubicin—bone cancer	0.000983	0.00165	CcSEcCtD
Acamprosate—Pollakiuria—Doxorubicin—bone cancer	0.000983	0.00165	CcSEcCtD
Acamprosate—GRIN2D—Alzheimers Disease—TP53—bone cancer	0.000978	0.00243	CbGpPWpGaD
Acamprosate—Haematuria—Epirubicin—bone cancer	0.000977	0.00164	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—SMO—bone cancer	0.000977	0.00243	CbGpPWpGaD
Acamprosate—Pharyngitis—Methotrexate—bone cancer	0.000976	0.00163	CcSEcCtD
Acamprosate—Photosensitivity reaction—Doxorubicin—bone cancer	0.000971	0.00163	CcSEcCtD
Acamprosate—Weight increased—Doxorubicin—bone cancer	0.000968	0.00162	CcSEcCtD
Acamprosate—GRIN2D—Transmission across Chemical Synapses—BRAF—bone cancer	0.000968	0.0024	CbGpPWpGaD
Acamprosate—Epistaxis—Epirubicin—bone cancer	0.000967	0.00162	CcSEcCtD
Acamprosate—Weight decreased—Doxorubicin—bone cancer	0.000962	0.00161	CcSEcCtD
Acamprosate—Hyperglycaemia—Doxorubicin—bone cancer	0.00096	0.00161	CcSEcCtD
Acamprosate—Pneumonia—Doxorubicin—bone cancer	0.000954	0.0016	CcSEcCtD
Acamprosate—Visual impairment—Methotrexate—bone cancer	0.000948	0.00159	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—RGS1—bone cancer	0.000945	0.00235	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—GRM4—bone cancer	0.000945	0.00235	CbGpPWpGaD
Acamprosate—Hypersensitivity—Cisplatin—bone cancer	0.000938	0.00157	CcSEcCtD
Acamprosate—Haemoglobin—Epirubicin—bone cancer	0.000925	0.00155	CcSEcCtD
Acamprosate—Stomatitis—Doxorubicin—bone cancer	0.000925	0.00155	CcSEcCtD
Acamprosate—Rhinitis—Epirubicin—bone cancer	0.000923	0.00154	CcSEcCtD
Acamprosate—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000922	0.00229	CbGpPWpGaD
Acamprosate—Urinary tract infection—Doxorubicin—bone cancer	0.000922	0.00154	CcSEcCtD
Acamprosate—Haemorrhage—Epirubicin—bone cancer	0.00092	0.00154	CcSEcCtD
Acamprosate—Hepatitis—Epirubicin—bone cancer	0.00092	0.00154	CcSEcCtD
Acamprosate—Tinnitus—Methotrexate—bone cancer	0.000917	0.00153	CcSEcCtD
Acamprosate—Hypoaesthesia—Epirubicin—bone cancer	0.000916	0.00153	CcSEcCtD
Acamprosate—Asthenia—Cisplatin—bone cancer	0.000913	0.00153	CcSEcCtD
Acamprosate—Pharyngitis—Epirubicin—bone cancer	0.000913	0.00153	CcSEcCtD
Acamprosate—Sweating—Doxorubicin—bone cancer	0.000909	0.00152	CcSEcCtD
Acamprosate—Oedema peripheral—Epirubicin—bone cancer	0.000907	0.00152	CcSEcCtD
Acamprosate—Haematuria—Doxorubicin—bone cancer	0.000904	0.00151	CcSEcCtD
Acamprosate—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000899	0.00223	CbGpPWpGaD
Acamprosate—GRIN1—EPH-Ephrin signaling—MMP9—bone cancer	0.000899	0.00223	CbGpPWpGaD
Acamprosate—Epistaxis—Doxorubicin—bone cancer	0.000895	0.0015	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—GNA11—bone cancer	0.000894	0.00222	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—IL3—bone cancer	0.000892	0.00222	CbGpPWpGaD
Acamprosate—Immune system disorder—Methotrexate—bone cancer	0.000888	0.00149	CcSEcCtD
Acamprosate—Visual impairment—Epirubicin—bone cancer	0.000887	0.00148	CcSEcCtD
Acamprosate—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000886	0.0022	CbGpPWpGaD
Acamprosate—Chills—Methotrexate—bone cancer	0.000882	0.00148	CcSEcCtD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000879	0.00218	CbGpPWpGaD
Acamprosate—GRIN2B—EPH-Ephrin signaling—MMP9—bone cancer	0.000876	0.00218	CbGpPWpGaD
Acamprosate—GRIN2C—Transmission across Chemical Synapses—MDM2—bone cancer	0.000872	0.00217	CbGpPWpGaD
Acamprosate—Diarrhoea—Cisplatin—bone cancer	0.000871	0.00146	CcSEcCtD
Acamprosate—Alopecia—Methotrexate—bone cancer	0.000869	0.00145	CcSEcCtD
Acamprosate—Mental disorder—Methotrexate—bone cancer	0.000862	0.00144	CcSEcCtD
Acamprosate—Tinnitus—Epirubicin—bone cancer	0.000858	0.00144	CcSEcCtD
Acamprosate—Malnutrition—Methotrexate—bone cancer	0.000856	0.00143	CcSEcCtD
Acamprosate—Haemoglobin—Doxorubicin—bone cancer	0.000856	0.00143	CcSEcCtD
Acamprosate—GRIN1—Spinal Cord Injury—PTGS2—bone cancer	0.000854	0.00212	CbGpPWpGaD
Acamprosate—Rhinitis—Doxorubicin—bone cancer	0.000854	0.00143	CcSEcCtD
Acamprosate—Haemorrhage—Doxorubicin—bone cancer	0.000852	0.00143	CcSEcCtD
Acamprosate—Hepatitis—Doxorubicin—bone cancer	0.000852	0.00143	CcSEcCtD
Acamprosate—Hypoaesthesia—Doxorubicin—bone cancer	0.000847	0.00142	CcSEcCtD
Acamprosate—Pharyngitis—Doxorubicin—bone cancer	0.000845	0.00141	CcSEcCtD
Acamprosate—Oedema peripheral—Doxorubicin—bone cancer	0.000839	0.0014	CcSEcCtD
Acamprosate—Dysgeusia—Methotrexate—bone cancer	0.000838	0.0014	CcSEcCtD
Acamprosate—Immune system disorder—Epirubicin—bone cancer	0.000831	0.00139	CcSEcCtD
Acamprosate—Back pain—Methotrexate—bone cancer	0.000828	0.00139	CcSEcCtD
Acamprosate—Chills—Epirubicin—bone cancer	0.000826	0.00138	CcSEcCtD
Acamprosate—Visual impairment—Doxorubicin—bone cancer	0.000821	0.00137	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—GRM1—bone cancer	0.000819	0.00203	CbGpPWpGaD
Acamprosate—Alopecia—Epirubicin—bone cancer	0.000813	0.00136	CcSEcCtD
Acamprosate—GRIN2D—Transmission across Chemical Synapses—MDM2—bone cancer	0.000811	0.00201	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—IL3—bone cancer	0.00081	0.00201	CbGpPWpGaD
Acamprosate—Vomiting—Cisplatin—bone cancer	0.00081	0.00136	CcSEcCtD
Acamprosate—Mental disorder—Epirubicin—bone cancer	0.000806	0.00135	CcSEcCtD
Acamprosate—GRIN2A—Alzheimers Disease—TP53—bone cancer	0.000803	0.00199	CbGpPWpGaD
Acamprosate—Rash—Cisplatin—bone cancer	0.000803	0.00134	CcSEcCtD
Acamprosate—Dermatitis—Cisplatin—bone cancer	0.000802	0.00134	CcSEcCtD
Acamprosate—Malnutrition—Epirubicin—bone cancer	0.000801	0.00134	CcSEcCtD
Acamprosate—GRIN2C—Neuronal System—BRAF—bone cancer	0.000798	0.00198	CbGpPWpGaD
Acamprosate—GRIN2A—Transmission across Chemical Synapses—BRAF—bone cancer	0.000795	0.00197	CbGpPWpGaD
Acamprosate—Ill-defined disorder—Methotrexate—bone cancer	0.000794	0.00133	CcSEcCtD
Acamprosate—Tinnitus—Doxorubicin—bone cancer	0.000794	0.00133	CcSEcCtD
Acamprosate—Anaemia—Methotrexate—bone cancer	0.000791	0.00132	CcSEcCtD
Acamprosate—Flatulence—Epirubicin—bone cancer	0.000789	0.00132	CcSEcCtD
Acamprosate—Tension—Epirubicin—bone cancer	0.000786	0.00132	CcSEcCtD
Acamprosate—Dysgeusia—Epirubicin—bone cancer	0.000785	0.00131	CcSEcCtD
Acamprosate—Nervousness—Epirubicin—bone cancer	0.000778	0.0013	CcSEcCtD
Acamprosate—Back pain—Epirubicin—bone cancer	0.000775	0.0013	CcSEcCtD
Acamprosate—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000773	0.00192	CbGpPWpGaD
Acamprosate—Malaise—Methotrexate—bone cancer	0.000772	0.00129	CcSEcCtD
Acamprosate—Muscle spasms—Epirubicin—bone cancer	0.00077	0.00129	CcSEcCtD
Acamprosate—Immune system disorder—Doxorubicin—bone cancer	0.000769	0.00129	CcSEcCtD
Acamprosate—Vertigo—Methotrexate—bone cancer	0.000769	0.00129	CcSEcCtD
Acamprosate—Leukopenia—Methotrexate—bone cancer	0.000766	0.00128	CcSEcCtD
Acamprosate—Chills—Doxorubicin—bone cancer	0.000764	0.00128	CcSEcCtD
Acamprosate—Nausea—Cisplatin—bone cancer	0.000756	0.00127	CcSEcCtD
Acamprosate—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000753	0.00187	CbGpPWpGaD
Acamprosate—Alopecia—Doxorubicin—bone cancer	0.000752	0.00126	CcSEcCtD
Acamprosate—GRIN1—Spinal Cord Injury—MMP9—bone cancer	0.000749	0.00186	CbGpPWpGaD
Acamprosate—Cough—Methotrexate—bone cancer	0.000747	0.00125	CcSEcCtD
Acamprosate—Mental disorder—Doxorubicin—bone cancer	0.000746	0.00125	CcSEcCtD
Acamprosate—Ill-defined disorder—Epirubicin—bone cancer	0.000743	0.00124	CcSEcCtD
Acamprosate—Convulsion—Methotrexate—bone cancer	0.000742	0.00124	CcSEcCtD
Acamprosate—GRIN2D—Neuronal System—BRAF—bone cancer	0.000741	0.00184	CbGpPWpGaD
Acamprosate—Malnutrition—Doxorubicin—bone cancer	0.000741	0.00124	CcSEcCtD
Acamprosate—Anaemia—Epirubicin—bone cancer	0.00074	0.00124	CcSEcCtD
Acamprosate—Agitation—Epirubicin—bone cancer	0.000736	0.00123	CcSEcCtD
Acamprosate—Flatulence—Doxorubicin—bone cancer	0.00073	0.00122	CcSEcCtD
Acamprosate—Arthralgia—Methotrexate—bone cancer	0.000729	0.00122	CcSEcCtD
Acamprosate—Chest pain—Methotrexate—bone cancer	0.000729	0.00122	CcSEcCtD
Acamprosate—Myalgia—Methotrexate—bone cancer	0.000729	0.00122	CcSEcCtD
Acamprosate—Tension—Doxorubicin—bone cancer	0.000727	0.00122	CcSEcCtD
Acamprosate—Dysgeusia—Doxorubicin—bone cancer	0.000726	0.00122	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000724	0.00121	CcSEcCtD
Acamprosate—Malaise—Epirubicin—bone cancer	0.000722	0.00121	CcSEcCtD
Acamprosate—GABRB3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000721	0.00179	CbGpPWpGaD
Acamprosate—Discomfort—Methotrexate—bone cancer	0.00072	0.00121	CcSEcCtD
Acamprosate—Nervousness—Doxorubicin—bone cancer	0.00072	0.00121	CcSEcCtD
Acamprosate—Vertigo—Epirubicin—bone cancer	0.00072	0.0012	CcSEcCtD
Acamprosate—Syncope—Epirubicin—bone cancer	0.000718	0.0012	CcSEcCtD
Acamprosate—Leukopenia—Epirubicin—bone cancer	0.000717	0.0012	CcSEcCtD
Acamprosate—Back pain—Doxorubicin—bone cancer	0.000717	0.0012	CcSEcCtD
Acamprosate—Muscle spasms—Doxorubicin—bone cancer	0.000713	0.00119	CcSEcCtD
Acamprosate—GABRG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000708	0.00176	CbGpPWpGaD
Acamprosate—Palpitations—Epirubicin—bone cancer	0.000708	0.00119	CcSEcCtD
Acamprosate—Confusional state—Methotrexate—bone cancer	0.000704	0.00118	CcSEcCtD
Acamprosate—Loss of consciousness—Epirubicin—bone cancer	0.000704	0.00118	CcSEcCtD
Acamprosate—GRIN1—Alzheimers Disease—TP53—bone cancer	0.000701	0.00174	CbGpPWpGaD
Acamprosate—Cough—Epirubicin—bone cancer	0.000699	0.00117	CcSEcCtD
Acamprosate—Anaphylactic shock—Methotrexate—bone cancer	0.000699	0.00117	CcSEcCtD
Acamprosate—Convulsion—Epirubicin—bone cancer	0.000694	0.00116	CcSEcCtD
Acamprosate—Infection—Methotrexate—bone cancer	0.000694	0.00116	CcSEcCtD
Acamprosate—GRIN1—Transmission across Chemical Synapses—BRAF—bone cancer	0.000693	0.00172	CbGpPWpGaD
Acamprosate—Hypertension—Epirubicin—bone cancer	0.000692	0.00116	CcSEcCtD
Acamprosate—Ill-defined disorder—Doxorubicin—bone cancer	0.000688	0.00115	CcSEcCtD
Acamprosate—Anaemia—Doxorubicin—bone cancer	0.000685	0.00115	CcSEcCtD
Acamprosate—Thrombocytopenia—Methotrexate—bone cancer	0.000684	0.00115	CcSEcCtD
Acamprosate—GRIN2B—Alzheimers Disease—TP53—bone cancer	0.000683	0.0017	CbGpPWpGaD
Acamprosate—Myalgia—Epirubicin—bone cancer	0.000682	0.00114	CcSEcCtD
Acamprosate—Arthralgia—Epirubicin—bone cancer	0.000682	0.00114	CcSEcCtD
Acamprosate—Chest pain—Epirubicin—bone cancer	0.000682	0.00114	CcSEcCtD
Acamprosate—Agitation—Doxorubicin—bone cancer	0.000681	0.00114	CcSEcCtD
Acamprosate—Anxiety—Epirubicin—bone cancer	0.00068	0.00114	CcSEcCtD
Acamprosate—Skin disorder—Methotrexate—bone cancer	0.000679	0.00114	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000677	0.00113	CcSEcCtD
Acamprosate—GRIN2B—Transmission across Chemical Synapses—BRAF—bone cancer	0.000676	0.00168	CbGpPWpGaD
Acamprosate—Hyperhidrosis—Methotrexate—bone cancer	0.000675	0.00113	CcSEcCtD
Acamprosate—Discomfort—Epirubicin—bone cancer	0.000674	0.00113	CcSEcCtD
Acamprosate—Malaise—Doxorubicin—bone cancer	0.000668	0.00112	CcSEcCtD
Acamprosate—GRIN2C—Neuronal System—MDM2—bone cancer	0.000668	0.00166	CbGpPWpGaD
Acamprosate—Dry mouth—Epirubicin—bone cancer	0.000667	0.00112	CcSEcCtD
Acamprosate—Vertigo—Doxorubicin—bone cancer	0.000666	0.00111	CcSEcCtD
Acamprosate—Anorexia—Methotrexate—bone cancer	0.000666	0.00111	CcSEcCtD
Acamprosate—GRIN2A—Transmission across Chemical Synapses—MDM2—bone cancer	0.000666	0.00165	CbGpPWpGaD
Acamprosate—Syncope—Doxorubicin—bone cancer	0.000665	0.00111	CcSEcCtD
Acamprosate—Leukopenia—Doxorubicin—bone cancer	0.000664	0.00111	CcSEcCtD
Acamprosate—Confusional state—Epirubicin—bone cancer	0.000659	0.0011	CcSEcCtD
Acamprosate—GRIN1—BDNF signaling pathway—JUN—bone cancer	0.000657	0.00163	CbGpPWpGaD
Acamprosate—Palpitations—Doxorubicin—bone cancer	0.000655	0.0011	CcSEcCtD
Acamprosate—Anaphylactic shock—Epirubicin—bone cancer	0.000654	0.00109	CcSEcCtD
Acamprosate—Hypotension—Methotrexate—bone cancer	0.000653	0.00109	CcSEcCtD
Acamprosate—Loss of consciousness—Doxorubicin—bone cancer	0.000652	0.00109	CcSEcCtD
Acamprosate—Infection—Epirubicin—bone cancer	0.00065	0.00109	CcSEcCtD
Acamprosate—Cough—Doxorubicin—bone cancer	0.000647	0.00108	CcSEcCtD
Acamprosate—Shock—Epirubicin—bone cancer	0.000643	0.00108	CcSEcCtD
Acamprosate—Convulsion—Doxorubicin—bone cancer	0.000642	0.00108	CcSEcCtD
Acamprosate—Thrombocytopenia—Epirubicin—bone cancer	0.00064	0.00107	CcSEcCtD
Acamprosate—GRIN2B—BDNF signaling pathway—JUN—bone cancer	0.00064	0.00159	CbGpPWpGaD
Acamprosate—Hypertension—Doxorubicin—bone cancer	0.00064	0.00107	CcSEcCtD
Acamprosate—Tachycardia—Epirubicin—bone cancer	0.000638	0.00107	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000637	0.00107	CcSEcCtD
Acamprosate—Skin disorder—Epirubicin—bone cancer	0.000635	0.00106	CcSEcCtD
Acamprosate—Hyperhidrosis—Epirubicin—bone cancer	0.000632	0.00106	CcSEcCtD
Acamprosate—Insomnia—Methotrexate—bone cancer	0.000632	0.00106	CcSEcCtD
Acamprosate—Arthralgia—Doxorubicin—bone cancer	0.000631	0.00106	CcSEcCtD
Acamprosate—Chest pain—Doxorubicin—bone cancer	0.000631	0.00106	CcSEcCtD
Acamprosate—Myalgia—Doxorubicin—bone cancer	0.000631	0.00106	CcSEcCtD
Acamprosate—Anxiety—Doxorubicin—bone cancer	0.000629	0.00105	CcSEcCtD
Acamprosate—Paraesthesia—Methotrexate—bone cancer	0.000627	0.00105	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000627	0.00105	CcSEcCtD
Acamprosate—Discomfort—Doxorubicin—bone cancer	0.000624	0.00104	CcSEcCtD
Acamprosate—Anorexia—Epirubicin—bone cancer	0.000623	0.00104	CcSEcCtD
Acamprosate—Dyspnoea—Methotrexate—bone cancer	0.000623	0.00104	CcSEcCtD
Acamprosate—GABRB3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000622	0.00155	CbGpPWpGaD
Acamprosate—GRIN2D—Neuronal System—MDM2—bone cancer	0.000621	0.00154	CbGpPWpGaD
Acamprosate—Somnolence—Methotrexate—bone cancer	0.000621	0.00104	CcSEcCtD
Acamprosate—GABRA1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000619	0.00154	CbGpPWpGaD
Acamprosate—Dry mouth—Doxorubicin—bone cancer	0.000617	0.00103	CcSEcCtD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—JUN—bone cancer	0.000616	0.00153	CbGpPWpGaD
Acamprosate—Dyspepsia—Methotrexate—bone cancer	0.000615	0.00103	CcSEcCtD
Acamprosate—GABRG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000611	0.00152	CbGpPWpGaD
Acamprosate—Hypotension—Epirubicin—bone cancer	0.000611	0.00102	CcSEcCtD
Acamprosate—Confusional state—Doxorubicin—bone cancer	0.00061	0.00102	CcSEcCtD
Acamprosate—GRIN2A—Neuronal System—BRAF—bone cancer	0.000609	0.00151	CbGpPWpGaD
Acamprosate—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000608	0.00151	CbGpPWpGaD
Acamprosate—Decreased appetite—Methotrexate—bone cancer	0.000607	0.00102	CcSEcCtD
Acamprosate—GRIN1—Spinal Cord Injury—EGFR—bone cancer	0.000605	0.0015	CbGpPWpGaD
Acamprosate—Anaphylactic shock—Doxorubicin—bone cancer	0.000605	0.00101	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Methotrexate—bone cancer	0.000603	0.00101	CcSEcCtD
Acamprosate—Infection—Doxorubicin—bone cancer	0.000601	0.00101	CcSEcCtD
Acamprosate—Pain—Methotrexate—bone cancer	0.000597	0.001	CcSEcCtD
Acamprosate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000597	0.00148	CbGpPWpGaD
Acamprosate—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000596	0.000997	CcSEcCtD
Acamprosate—Shock—Doxorubicin—bone cancer	0.000595	0.000996	CcSEcCtD
Acamprosate—Thrombocytopenia—Doxorubicin—bone cancer	0.000592	0.000992	CcSEcCtD
Acamprosate—Insomnia—Epirubicin—bone cancer	0.000591	0.00099	CcSEcCtD
Acamprosate—Tachycardia—Doxorubicin—bone cancer	0.00059	0.000988	CcSEcCtD
Acamprosate—Skin disorder—Doxorubicin—bone cancer	0.000588	0.000984	CcSEcCtD
Acamprosate—Paraesthesia—Epirubicin—bone cancer	0.000587	0.000983	CcSEcCtD
Acamprosate—Hyperhidrosis—Doxorubicin—bone cancer	0.000585	0.000979	CcSEcCtD
Acamprosate—Dyspnoea—Epirubicin—bone cancer	0.000583	0.000976	CcSEcCtD
Acamprosate—Somnolence—Epirubicin—bone cancer	0.000581	0.000973	CcSEcCtD
Acamprosate—GRIN1—Transmission across Chemical Synapses—MDM2—bone cancer	0.000581	0.00144	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—SMO—bone cancer	0.000577	0.00143	CbGpPWpGaD
Acamprosate—Anorexia—Doxorubicin—bone cancer	0.000577	0.000965	CcSEcCtD
Acamprosate—Feeling abnormal—Methotrexate—bone cancer	0.000576	0.000964	CcSEcCtD
Acamprosate—Dyspepsia—Epirubicin—bone cancer	0.000576	0.000964	CcSEcCtD
Acamprosate—Gastrointestinal pain—Methotrexate—bone cancer	0.000571	0.000956	CcSEcCtD
Acamprosate—Decreased appetite—Epirubicin—bone cancer	0.000568	0.000952	CcSEcCtD
Acamprosate—GRIN2B—Transmission across Chemical Synapses—MDM2—bone cancer	0.000566	0.00141	CbGpPWpGaD
Acamprosate—Hypotension—Doxorubicin—bone cancer	0.000565	0.000946	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Epirubicin—bone cancer	0.000564	0.000945	CcSEcCtD
Acamprosate—Constipation—Epirubicin—bone cancer	0.000559	0.000936	CcSEcCtD
Acamprosate—Pain—Epirubicin—bone cancer	0.000559	0.000936	CcSEcCtD
Acamprosate—Urticaria—Methotrexate—bone cancer	0.000555	0.000929	CcSEcCtD
Acamprosate—Abdominal pain—Methotrexate—bone cancer	0.000552	0.000925	CcSEcCtD
Acamprosate—Body temperature increased—Methotrexate—bone cancer	0.000552	0.000925	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000551	0.000923	CcSEcCtD
Acamprosate—Insomnia—Doxorubicin—bone cancer	0.000547	0.000916	CcSEcCtD
Acamprosate—Paraesthesia—Doxorubicin—bone cancer	0.000543	0.000909	CcSEcCtD
Acamprosate—Dyspnoea—Doxorubicin—bone cancer	0.000539	0.000903	CcSEcCtD
Acamprosate—Feeling abnormal—Epirubicin—bone cancer	0.000539	0.000902	CcSEcCtD
Acamprosate—Somnolence—Doxorubicin—bone cancer	0.000538	0.0009	CcSEcCtD
Acamprosate—Gastrointestinal pain—Epirubicin—bone cancer	0.000535	0.000895	CcSEcCtD
Acamprosate—GABRA1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000534	0.00133	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—MET—bone cancer	0.000533	0.00132	CbGpPWpGaD
Acamprosate—Dyspepsia—Doxorubicin—bone cancer	0.000533	0.000892	CcSEcCtD
Acamprosate—GRIN1—Neuronal System—BRAF—bone cancer	0.000531	0.00132	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—GNA11—bone cancer	0.000528	0.00131	CbGpPWpGaD
Acamprosate—Decreased appetite—Doxorubicin—bone cancer	0.000526	0.00088	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000522	0.000874	CcSEcCtD
Acamprosate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000522	0.0013	CbGpPWpGaD
Acamprosate—Urticaria—Epirubicin—bone cancer	0.000519	0.00087	CcSEcCtD
Acamprosate—GRIN2B—Axon guidance—MET—bone cancer	0.000519	0.00129	CbGpPWpGaD
Acamprosate—GRIN2B—Neuronal System—BRAF—bone cancer	0.000518	0.00129	CbGpPWpGaD
Acamprosate—Pain—Doxorubicin—bone cancer	0.000517	0.000866	CcSEcCtD
Acamprosate—Constipation—Doxorubicin—bone cancer	0.000517	0.000866	CcSEcCtD
Acamprosate—Abdominal pain—Epirubicin—bone cancer	0.000517	0.000865	CcSEcCtD
Acamprosate—Body temperature increased—Epirubicin—bone cancer	0.000517	0.000865	CcSEcCtD
Acamprosate—Hypersensitivity—Methotrexate—bone cancer	0.000515	0.000862	CcSEcCtD
Acamprosate—GRIN2A—Neuronal System—MDM2—bone cancer	0.00051	0.00127	CbGpPWpGaD
Acamprosate—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.00051	0.00127	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—TP53—bone cancer	0.000508	0.00126	CbGpPWpGaD
Acamprosate—Asthenia—Methotrexate—bone cancer	0.000501	0.000839	CcSEcCtD
Acamprosate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.0005	0.00124	CbGpPWpGaD
Acamprosate—Feeling abnormal—Doxorubicin—bone cancer	0.000499	0.000835	CcSEcCtD
Acamprosate—Gastrointestinal pain—Doxorubicin—bone cancer	0.000495	0.000828	CcSEcCtD
Acamprosate—Pruritus—Methotrexate—bone cancer	0.000494	0.000828	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—ATF1—bone cancer	0.000491	0.00122	CbGpPWpGaD
Acamprosate—Hypersensitivity—Epirubicin—bone cancer	0.000482	0.000806	CcSEcCtD
Acamprosate—Urticaria—Doxorubicin—bone cancer	0.000481	0.000805	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—IL3—bone cancer	0.000479	0.00119	CbGpPWpGaD
Acamprosate—Abdominal pain—Doxorubicin—bone cancer	0.000478	0.000801	CcSEcCtD
Acamprosate—Body temperature increased—Doxorubicin—bone cancer	0.000478	0.000801	CcSEcCtD
Acamprosate—Diarrhoea—Methotrexate—bone cancer	0.000478	0.0008	CcSEcCtD
Acamprosate—Asthenia—Epirubicin—bone cancer	0.000469	0.000785	CcSEcCtD
Acamprosate—Pruritus—Epirubicin—bone cancer	0.000463	0.000774	CcSEcCtD
Acamprosate—Dizziness—Methotrexate—bone cancer	0.000462	0.000773	CcSEcCtD
Acamprosate—GABRB3—Transmission across Chemical Synapses—BRAF—bone cancer	0.000457	0.00114	CbGpPWpGaD
Acamprosate—GABRG2—Transmission across Chemical Synapses—BRAF—bone cancer	0.000449	0.00112	CbGpPWpGaD
Acamprosate—Diarrhoea—Epirubicin—bone cancer	0.000447	0.000749	CcSEcCtD
Acamprosate—Hypersensitivity—Doxorubicin—bone cancer	0.000446	0.000746	CcSEcCtD
Acamprosate—GRIN1—Neuronal System—MDM2—bone cancer	0.000445	0.00111	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—MMP2—bone cancer	0.000444	0.0011	CbGpPWpGaD
Acamprosate—Vomiting—Methotrexate—bone cancer	0.000444	0.000744	CcSEcCtD
Acamprosate—Rash—Methotrexate—bone cancer	0.000441	0.000737	CcSEcCtD
Acamprosate—Dermatitis—Methotrexate—bone cancer	0.00044	0.000737	CcSEcCtD
Acamprosate—Headache—Methotrexate—bone cancer	0.000438	0.000733	CcSEcCtD
Acamprosate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000437	0.00109	CbGpPWpGaD
Acamprosate—Asthenia—Doxorubicin—bone cancer	0.000434	0.000727	CcSEcCtD
Acamprosate—GRIN2B—Neuronal System—MDM2—bone cancer	0.000434	0.00108	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—JUN—bone cancer	0.000433	0.00108	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—MMP2—bone cancer	0.000433	0.00108	CbGpPWpGaD
Acamprosate—Dizziness—Epirubicin—bone cancer	0.000432	0.000724	CcSEcCtD
Acamprosate—Pruritus—Doxorubicin—bone cancer	0.000428	0.000717	CcSEcCtD
Acamprosate—Vomiting—Epirubicin—bone cancer	0.000416	0.000696	CcSEcCtD
Acamprosate—Nausea—Methotrexate—bone cancer	0.000415	0.000695	CcSEcCtD
Acamprosate—Diarrhoea—Doxorubicin—bone cancer	0.000414	0.000693	CcSEcCtD
Acamprosate—Rash—Epirubicin—bone cancer	0.000412	0.00069	CcSEcCtD
Acamprosate—Dermatitis—Epirubicin—bone cancer	0.000412	0.00069	CcSEcCtD
Acamprosate—Headache—Epirubicin—bone cancer	0.00041	0.000686	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—TGFBR2—bone cancer	0.000409	0.00102	CbGpPWpGaD
Acamprosate—Dizziness—Doxorubicin—bone cancer	0.0004	0.00067	CcSEcCtD
Acamprosate—GABRA1—Transmission across Chemical Synapses—BRAF—bone cancer	0.000393	0.000975	CbGpPWpGaD
Acamprosate—Nausea—Epirubicin—bone cancer	0.000388	0.00065	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—IGF1R—bone cancer	0.000385	0.000956	CbGpPWpGaD
Acamprosate—Vomiting—Doxorubicin—bone cancer	0.000385	0.000644	CcSEcCtD
Acamprosate—GABRB3—Transmission across Chemical Synapses—MDM2—bone cancer	0.000383	0.000952	CbGpPWpGaD
Acamprosate—Rash—Doxorubicin—bone cancer	0.000381	0.000639	CcSEcCtD
Acamprosate—Dermatitis—Doxorubicin—bone cancer	0.000381	0.000638	CcSEcCtD
Acamprosate—GRIN1—Developmental Biology—MET—bone cancer	0.00038	0.000944	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—CDK4—bone cancer	0.00038	0.000944	CbGpPWpGaD
Acamprosate—Headache—Doxorubicin—bone cancer	0.000379	0.000634	CcSEcCtD
Acamprosate—GABRG2—Transmission across Chemical Synapses—MDM2—bone cancer	0.000376	0.000934	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—CDK4—bone cancer	0.00037	0.00092	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—MET—bone cancer	0.00037	0.00092	CbGpPWpGaD
Acamprosate—Nausea—Doxorubicin—bone cancer	0.000359	0.000602	CcSEcCtD
Acamprosate—GABRB3—Neuronal System—BRAF—bone cancer	0.00035	0.00087	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—JUN—bone cancer	0.000349	0.000866	CbGpPWpGaD
Acamprosate—GABRG2—Neuronal System—BRAF—bone cancer	0.000344	0.000854	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—MMP9—bone cancer	0.000334	0.000829	CbGpPWpGaD
Acamprosate—GABRA1—Transmission across Chemical Synapses—MDM2—bone cancer	0.000329	0.000817	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—MMP9—bone cancer	0.000325	0.000808	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—MMP2—bone cancer	0.000317	0.000787	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—MMP2—bone cancer	0.000309	0.000767	CbGpPWpGaD
Acamprosate—GABRA1—Neuronal System—BRAF—bone cancer	0.000301	0.000747	CbGpPWpGaD
Acamprosate—GABRB3—Neuronal System—MDM2—bone cancer	0.000294	0.000729	CbGpPWpGaD
Acamprosate—GABRG2—Neuronal System—MDM2—bone cancer	0.000288	0.000716	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—KIT—bone cancer	0.000279	0.000694	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—EGFR—bone cancer	0.00027	0.00067	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—EGFR—bone cancer	0.000263	0.000653	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—BRAF—bone cancer	0.000263	0.000652	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—EGFR—bone cancer	0.000254	0.000632	CbGpPWpGaD
Acamprosate—GABRA1—Neuronal System—MDM2—bone cancer	0.000252	0.000626	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—MMP9—bone cancer	0.000238	0.000592	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—MMP9—bone cancer	0.000232	0.000577	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—MDM2—bone cancer	0.00022	0.000546	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—EGFR—bone cancer	0.000193	0.000478	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—JUN—bone cancer	0.000191	0.000475	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—EGFR—bone cancer	0.000188	0.000466	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—MMP9—bone cancer	0.000186	0.000462	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—EGFR—bone cancer	0.00015	0.000373	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—TP53—bone cancer	0.000126	0.000313	CbGpPWpGaD
